BPTH

1.16

0.87% 0.01

Handel nachbörslich: 1.14 -0.02 -1.72%

Bio Path Holdings Inc (BPTH)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$1.15

Offen:

$1.18

24-Stunden-Volumen:

342.26K

Relative Volume:

0.11

Marktkapitalisierung:

$5.00M

Einnahmen:

Nettoeinkommen (Verlust:

$-16.08M

KGV:

-0.0337

EPS:

-34.43

Netto-Cashflow:

$-11.54M

1W Leistung:

+1.75%

1M Leistung:

+63.38%

6M Leistung:

-34.83%

1J Leistung:

-88.19%

1-Tages-Spanne:

$1.13

$1.21

1-Wochen-Bereich:

$1.11

$1.34

52-Wochen-Spanne:

$0.5933

$12.00

Bio Path Holdings Inc Stock (BPTH) Company Profile

Firmenname

Bio Path Holdings Inc

Sektor

Healthcare (1174)

Branche

Biotechnology (669)

Telefon

(832) 742-1357

Adresse

4710 BELLAIRE BOULEVARD, BELLAIRE, TX

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-12-15

Neueste SEC-Einreichungen

BPTH's Discussions on Twitter

Vergleichen Sie BPTH mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BPTH Bio Path Holdings Inc	1.16	5.00M	0	-16.08M	-11.54M	-34.43
VRTX Vertex Pharmaceuticals Inc	407.11	104.84B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	718.15	78.92B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	621.29	37.15B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	234.28	30.22B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	115.79	27.76B	3.30B	-501.07M	1.03B	-2.1146

Bio Path Holdings Inc Stock (BPTH) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2021-03-11	Eingeleitet	ROTH Capital	Buy
2017-11-13	Bestätigt	H.C. Wainwright	Buy
2016-08-10	Bestätigt	Maxim Group	Buy
2016-04-18	Eingeleitet	Rodman & Renshaw	Buy
2014-06-02	Fortgesetzt	Maxim Group	Buy
2014-05-09	Eingeleitet	Maxim Group	Buy

Alle ansehen

Bio Path Holdings Inc Aktie (BPTH) Neueste Nachrichten

Jan 03, 2025

Bio-Path (NASDAQ:BPTH) Earns Sell Rating from Analysts at StockNews.com - Defense World

Jan 03, 2025

Dec 29, 2024

Is This Penny Stock a Buy After a 180% Rally? - MSN

Dec 29, 2024

Is This Penny Stock A Buy After A 180% Rally? - Barchart

Dec 29, 2024

Bio-Path Holdings Advances Clinical Trials and Secures $4 Million in Funding - Citybuzz

Dec 29, 2024

Dec 26, 2024

Bio-Path (NASDAQ:BPTH) Now Covered by Analysts at StockNews.com - Defense World

Dec 26, 2024

Dec 20, 2024

Studies of Bio-path’s BP-1001-A show potential in obesity, diabetes - BioWorld Online

Dec 20, 2024

Bio-Path Rockets To 4-Month High As Obesity Drug Shows Promise For Diabetes: Retail In Celebration Mode - Asianet Newsable

Dec 20, 2024

Bio-Path Holdings (BPTH) Surges Over 406% Following Positive Pre - GuruFocus.com

Dec 20, 2024

Dec 19, 2024

Bio-Path More Than Doubles on Preclinical Results of BP1001-A for Obesity - MarketWatch

Dec 19, 2024

Industry Leader Climet Partners with Phizzle; One of the First Joint TCO/ROI Value Proposition in Pharma Manufacturing - Newsfile

Dec 19, 2024

Bio-Path Holdings Shares Were On The Rise: What's Going On? - Benzinga

Dec 19, 2024

Gold Falls Sharply, Lamb Weston Shares Plunge - Benzinga

Dec 19, 2024

Innovative therapies and military tech drive early trading gains - RagingBull

Dec 19, 2024

Stock Market Movers Today • Top Gainers & Losers - Benzinga

Dec 19, 2024

Artificial Intelligence (AI) News Live Feed - StockTitan

Dec 19, 2024

Wall Street-Heavily Traded - WDRB

Dec 19, 2024

Bio-Path (BPTH) Stock Rides High On Promising Trial Results - Stocks Telegraph

Dec 19, 2024

Clinical Trials News Live Feed - StockTitan

Dec 19, 2024

Bio-Path reports potential obesity treatment success - Investing.com

Dec 19, 2024

Bio-Path's Breakthrough Drug Shows Promise in Diabetes Treatment, Phase 1 Trial Set for 2025 - StockTitan

Dec 19, 2024

Dec 18, 2024

Bio-Path (NASDAQ:BPTH) Now Covered by StockNews.com - Defense World

Dec 18, 2024

Dec 17, 2024

VueReal Showcases Industry-First MicroLED Design Reference Kits at CES 2025, Driving Global Innovation Across Key Industries - Newsfile

Dec 17, 2024

Bio-Path Holdings Faces Nasdaq Compliance and Strategic Changes - MSN

Dec 17, 2024

Dec 16, 2024

Bullfrog AI CFO Passes Away - Defense World

Dec 16, 2024

Rafael Holdings Reports First Quarter Fiscal 2025 Financial ResultsNEWARK, NJ – December 11, 2024 – Rafael Holdings, Inc. (NYSE: RFL) released its financial results for the first quarter of fiscal year 2025, ended October 31, 2024. The company announ - Defense World

Dec 16, 2024

Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients - Defense World

Dec 16, 2024

Dec 14, 2024

Bio-Path Holdings faces Nasdaq delisting over share price By Investing.com - Investing.com Australia

Dec 14, 2024

Bio-Path Holdings faces Nasdaq delisting over share price - Investing.com

Dec 14, 2024

Dec 13, 2024

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 24 - The Kingston Whig-Standard

Dec 13, 2024

Dec 12, 2024

Bio-Path Holdings Shifts Focus to Metabolic Program - TipRanks

Dec 12, 2024

CNB Financial Services, Inc. goes ex dividend tomorrow - MSN

Dec 12, 2024

VueReal Highlights Revolutionary MicroLED Solutions at CES 2025 - Newsfile

Dec 12, 2024

Bio-Path refocuses on diabetes drug amid trial challenges By Investing.com - Investing.com South Africa

Dec 12, 2024

Dec 11, 2024

Stonegate Capital Partners Updates Coverage on Aemetis, Inc. (AMTX) Q3 2024 - Newsfile

Dec 11, 2024

Bio-Path refocuses on diabetes drug amid trial challenges - Investing.com India

Dec 11, 2024

Tecnoglass Sets Record Date for Previously-Announced 36% Increase to Fourth Quarter 2024 Dividend - The Manila Times

Dec 11, 2024

Bio-Path Pivots to Diabetes Drug Development, Unveils Strategic Shift in Clinical Pipeline - StockTitan

Dec 11, 2024

Dec 06, 2024

BPTH stock touches 52-week low at $0.6 amid sharp annual decline - Investing.com Canada

Dec 06, 2024

Full Stock Market News from 2024-12-06 - StockTitan

Dec 06, 2024

Nov 29, 2024

Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve

Nov 29, 2024

Nov 26, 2024

StockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH) - Defense World

Nov 26, 2024

Nov 23, 2024

Bio-Path Holdings Expands DNAbilize® Technology Applications - MSN

Nov 23, 2024

Nov 21, 2024

Bio-Path (BPTH) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - MSN

Nov 21, 2024